Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) saw unusually-strong trading volume on Monday . Approximately 25,958 shares were traded during trading, a decline of 97% from the previous session's volume of 928,630 shares.The stock last traded at $10.62 and had previously closed at $10.07.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and set a $12.00 price target on shares of Theravance Biopharma in a research note on Thursday, July 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.75.
Get
Theravance Biopharma alerts:
Theravance Biopharma Price Performance
The stock has a 50-day moving average of $9.24 and a 200 day moving average of $9.32.
Theravance Biopharma (NASDAQ:TBPH – Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $11.05 million during the quarter, compared to analysts' expectations of $17.47 million. During the same quarter in the prior year, the company earned ($0.80) EPS. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -0.85 EPS for the current year.
Insider Activity at Theravance Biopharma
In related news, SVP Richard A. Graham sold 15,086 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $8.79, for a total value of $132,605.94. Following the sale, the senior vice president now owns 369,651 shares in the company, valued at $3,249,232.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Theravance Biopharma news, SVP Richard A. Graham sold 4,906 shares of the business's stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $9.71, for a total value of $47,637.26. Following the completion of the transaction, the senior vice president now directly owns 364,745 shares of the company's stock, valued at $3,541,673.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard A. Graham sold 15,086 shares of the business's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $8.79, for a total value of $132,605.94. Following the completion of the transaction, the senior vice president now directly owns 369,651 shares of the company's stock, valued at $3,249,232.29. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its holdings in Theravance Biopharma by 611.1% in the fourth quarter. BNP Paribas Arbitrage SA now owns 76,725 shares of the biopharmaceutical company's stock valued at $848,000 after acquiring an additional 65,935 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $115,000. CM Management LLC raised its stake in shares of Theravance Biopharma by 140.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biopharmaceutical company's stock worth $1,147,000 after buying an additional 70,000 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Theravance Biopharma during the 1st quarter worth approximately $106,000. Finally, King Wealth raised its stake in shares of Theravance Biopharma by 838.5% during the 1st quarter. King Wealth now owns 122,000 shares of the biopharmaceutical company's stock worth $1,166,000 after buying an additional 109,000 shares during the period.
About Theravance Biopharma
(Get Rating)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Featured Articles
- Get a free copy of the StockNews.com research report on Theravance Biopharma (TBPH)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
